vTv Therapeutics Inc. Accelerates Type 1 Diabetes Trial with Protocol Amendment

In a significant development for the biotechnology sector, vTv Therapeutics Inc., a clinical-stage pharmaceutical company, has announced the reinitiation of screening in its CATT1 Phase 3 trial. This trial is evaluating cadisegliatin, a potential first-in-class, liver-selective glucokinase activator, as an adjunctive treatment for type 1 diabetes (T1D). The company, headquartered in High Point, North Carolina, has made strides in advancing its lead program in diabetes, which is part of its broader mission to revolutionize patient care through novel therapeutic agents.

The CATT1 trial, which has been granted Breakthrough Therapy designation by the FDA, is now set to conclude in half the originally planned time. The protocol amendment shortens the trial duration from 12 months to 6 months, expediting the timeline to topline data expected in the second half of 2026. This strategic move is anticipated to accelerate the development process, potentially bringing a new treatment option to market more swiftly.

Paul Sekhri, Chairman, President, and Chief Executive Officer of vTv Therapeutics, expressed enthusiasm about the trial’s progress. “We are thrilled that we have resumed our CATT1 Phase 3 trial and screened a subject under the amended protocol,” Sekhri stated. “The amendment to the protocol will help expedite time to both topline data and, ultimately, a potential new treatment option for patients with type 1 diabetes.”

The company’s focus on addressing unmet medical needs in the diabetes space aligns with its broader strategy within the health care sector. With a market capitalization of approximately $52.45 million and a close price of $20.8 as of May 12, 2025, vTv Therapeutics continues to position itself as a key player in the biotechnology industry.

As the company moves forward, stakeholders and investors are closely watching the developments in the CATT1 trial. The successful completion and positive results of this trial could significantly impact vTv Therapeutics’ market position and financial performance, potentially leading to increased investor confidence and stock value.

In summary, vTv Therapeutics Inc. is making notable progress in its efforts to develop innovative treatments for type 1 diabetes. The reinitiation of the CATT1 Phase 3 trial, coupled with the protocol amendment, underscores the company’s commitment to expediting the delivery of new therapeutic options to patients, reinforcing its role as a leader in the biotechnology sector.